Blue Vision A/S
BLVIS-A.CO
NASDAQ Copenhagen0.93
DKK
+0.22
- -
Blue Vision A/S
BLVIS-A.CO
(NASDAQ Copenhagen)
Recent
price
0.93
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Blue Vision A/S (BLVIS-A.CO) is a Denmark-based investment holding company that acquires and manages stakes in life science and biotechnology firms; invests in equities, real estate, mortgage deeds, and other diversified assets on regulated markets and multilateral trading facilities; and pursues long-term value growth through risk-diversified portfolios without geographic limitations. Incorporated in 2002 and headquartered at Slotsmarken 18, 2nd floor, 2970 Hørsholm, Denmark, the company operates primarily in the financial services and life sciences sectors, targeting biopharmaceutical treatments for serious inflammatory diseases and innovative biotech solutions with global reach. Core activities encompass portfolio management of listed and unlisted shares; strategic holdings in biotechnology developers addressing unmet medical needs; and opportunistic investments in real assets including property and debt instruments. In recent developments, Blue Vision A/S underwent a name change proposal to Pharma Equity Group A/S in February 2023, aligning with its sharpened focus on pharmaceutical equities while retaining the BLVIS-A.CO ticker; appointed Christian Henrik Tange as CEO effective April 1, 2024, alongside executive management and organizational restructuring; issued convertible loans per board authorization to bolster funding flexibility; and released interim reports in August 2025 alongside earnings updates, reflecting ongoing portfolio adjustments and regulatory compliance in a dynamic investment landscape.